Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
RARapport Therapeutics, Inc. logo

Rapport Therapeutics, Inc. (RAPP)

NASDAQ Global Market · Currency in USD
$25.93 ▼ -0.60 (-2.26%)
At close: Oct 23, 4:00 PM ET. Market closed.
$25.75 ▼ -0.18 (-0.69%)
After hours: Oct 23, 7:31 PM ET

Summary

Previous Close
$26.53
Open
$27.54
Day's Range
$25.71 – $27.76
52 Week Range
$23.75 – $52.93
Volume
1,180,771
Avg. Volume
508,314
Market Cap
$1.24B
Beta (5Y Monthly)
1.03
PE Ratio (TTM)
--
EPS (TTM)
-$2.89
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$65.56

Profile: Rapport Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
84
CEO
Abraham N. Ceesay

Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$1.20
DateEst.Actual
Aug 5, 2026-$0.96-$1.19Miss
May 7, 2026-$0.56-$0.42Beat
Mar 10, 2026-$0.65-$0.72Miss
Nov 6, 2025-$0.77-$0.71Beat
Aug 7, 2025-$0.87-$0.75Beat
May 8, 2025-$0.77-$0.68Beat

Analyst view

Consensus price target
$65.56 ▲ +152.8%
Range $50.00 – $89.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on RAPP and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.